Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC)

Authors :: Ana Isabel Lavado Fernandez
Cristina Fernandez-Sousa
Vanessa de Luque
Elisabeth Perez Ruiz
Nuria Ribelles
Pedro Sánchez Rovira
C González-Hermoso
Sean Ferree
Luis Vicioso
Arthur Jeiranian
Aleix Prat
Martina Alvarez
Emilio Alba
Begona Jimenez Rodriguez
Cesar Ramirez Tortosa
Angela Santonja
Wesley Buckingham
Naeem Dowidar
M Rosario Chica Parrado
Carl Schaper
Source :: Journal of Clinical Oncology. 33:569-569
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: 569 Background: Pathological complete response following NAC is associated with improved survival. CESP is a novel algorithm derived from the GEICAM 2006-03 clinical trial which is based on the ass...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
business.industry
medicine.medical_treatment
HER2 negative
medicine.disease
Clinical trial
Breast cancer
Hormone receptor
Internal medicine
Endocrine system
Medicine
business
Pathological
Complete response

Full Text Access

Tools